Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Budesonide inhalation suspension - AstraZeneca

Next Previous
X
Search
Drug Profile

Budesonide inhalation suspension - AstraZeneca

Alternative Names: Pulmicort Respules; S1320 inhalation suspension - AstraZeneca

Latest Information Update: 16 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma
  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 16 Feb 2022 AstraZeneca and Glenmark Pharmaceuticals Ltd enter in to exclusive licensing agreement for Budesonide inhalation suspension in Colombia
  • 17 Feb 2015 The United States District Court for the District of New Jersey invalidates the US Patent No. 7 524 834
  • 01 Aug 2012 Generic equivalent from Actavis approved in the US

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top